SUMMARY A 27 month old girl with congenital microvillus atrophy received two courses of SMS 201-995, a synthetic long acting analogue of native somatostatin, in an attempt to decrease profuse secretory diarrhoea. During the first trial at 13 months of age fluid and electrolytes administered by parenteral infusion were decreased as measured by water and faecal electrolyte losses. During the second trial of SMS 201-995 at 19 months fluid and electrolyte input were held constant for 14 days. Stool volume declined from 275 ml/kg to 161 ml/kg. Reductions in output of stool electrolytes (Nal, K+, Cl-) were accompanied by an increase in urine fluid output and increased excretion of urinary Nal. Subsequent administration of SMS 201-995 for a nine month period was not associated with adverse side effects or an impairment of growth velocity. These findings suggest that SMS 201-995 may be useful therapy in infants with high output diarrhoea as a result of congenital microvillus atrophy.
losses, all forms of pharmacological interventions used to date have not been successful. '-5 SMS 201-995 is a potent longacting analogue of native somatostatin. It is effective in the treatment of a variety of severe secretory diarrhoeal disorders. For example, SMS 201-995 has been used with success in adults with vasoactive intestinal peptide secreting tumours,6 high output ileostomy diarrhoea,7 diabetic diarrhoea,' and cryptosporidiosis.9 In this report we describe the clinical response to SMS 201-995 in an infant with congenital microvillus atrophy.
Case history
A 27 month old girl first presented at three days of age with profuse watery diarrhoea, dehydration, and metabolic acidosis. The pregnancy was uncomplicated without evidence of polyhydramnios and birthweight was 2-3 kg at term gestation. Her throughout the trial (Table) . Total stool losses of sodium and potassium decreased, however, in parallel with the reduction of total stool volume.
Daily urine output increased from 23.5 ml/kg before treatment to a maximum output of 87 ml/kg at day 7. Urinary electrolytes showed increasing concentrations of sodium and decreasing concentrations of potassium during the trial (Table) . Further evidence of an improvement in fluid and electrolyte homeostasis during the second course of SMS The second approach to therapy recognises that the consequences of the high volume of stool output are dehydration, intravascular volume depletion and metabolic derangements. Therefore, there have also been attempts to diminish high output stool losses in patients with congenital microvillus atrophy by the use of antisecretory agents. For example, loperamide' and native somatostatin3 have been used in previous therapeutic trials. Schmitz et all reported that native somatostatin reduced ileostomy fluid losses by 40% in one patient with congenital microvillus atrophy. Native somatostatin must be given by continuous intravenous infusion, however, because of its short duration of action. Therefore, it is impractical for longterm management.
In this open trial of SMS 201-995 administration to a child with congenital microvillus atrophy the daily stool output of water and electrolytes were markedly reduced. The decrease in stool output was accompanied by an increase in urine output, decreased 1~~~1 022 group.bmj.com on July 1, 2017 -Published by http://gut.bmj.com/ Downloaded from specific gravity of the urine, increased natriuresis, decreased concentrations of serum aldosterone and a decline in plasma renin. These metabolic changes, which occurred in the second course of therapy during a period in which intake of fluids and electrolytes were kept constant, suggest a clinically relevant antisecretory response.
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